|
Endocrine Therapy for Metastatic Disease: Select publications |
Abrial C et al. Aromatase inhibitors and
metastatic breast cancer survival. Proc ASCO 2005;Abstract 767.
Bundred N. Preclinical and clinical experience
with fulvestrant (Faslodex) in postmenopausal
women with hormone receptor-positive advanced
breast cancer. Cancer Invest 2005;23(2):173-81.
Abstract
Buzdar AU. Hormonal therapy in early and
advanced breast cancer. Breast J 2004;10(Suppl
1):19-21. Abstract
Buzdar AU et al. The impact of hormone
receptor status on the clinical efficacy of the
new-generation aromatase inhibitors: A review
of data from first-line metastatic disease trials in
postmenopausal women. Breast J 2004;10(3):211-
7. Abstract
Cameron DA et al. A comparative study of
exemestane versus anastrozole in postmenopausal
breast cancer subjects with visceral
disease. Proc ASCO 2004;Abstract 628.
Cardoso AA et al. Fulvestrant after aromatase
inhibitor failure: Results from the expanded
access program in Rio de Janeiro, Brazil. Breast Cancer Res Treat 2004;Abstract 6050.
Carlini P et al. New aromatase inhibitors (Als) as
first-line endocrine therapy (ET) in metastatic
breast cancer (MBC): A pooled analysis of
3238 women from 8 phase III trials. Proc ASCO 2005;Abstract 602.
Carlson RW et al. Goserelin plus anastrozole
for the treatment of premenopausal women
with hormone receptor positive, recurrent/
metastatic breast cancer. Breast Cancer Res Treat 2004;Abstract 6052.
Cheung K et al. Goserelin plus anastrozole as
first-line endocrine therapy for premenopausal
women with oestrogen receptor (ER) positive
advanced breast cancer (ABC). Proc ASCO 2005;Abstract 731.
Come SE, Borges VF. Role of fulvestrant in
sequential hormonal therapy for advanced,
hormone receptor-positive breast cancer in
postmenopausal women. Clin Breast Cancer
2005;6 Suppl 1:S15-22. Abstract
Dixon JM. Exemestane and aromatase inhibitors
in the management of advanced breast cancer. Expert Opin Pharmacother 2004;5(2):307-16.
Abstract
Dodwell D, Vergote I. A comparison of
fulvestrant and the third-generation aromatase
inhibitors in the second-line treatment of
postmenopausal women with advanced breast
cancer. Cancer Treat Rev 2005;31(4):274-82.
Abstract
Dodwell D, Vergote I. Fulvestrant: A new,
effective and well-tolerated second-line treatment
option for postmenopausal women with
advanced breast cancer. Breast Cancer Res Treat 2004;Abstract 6051.
Dowsett M et al. Biological characteristics of
the pure antiestrogen fulvestrant: Overcoming
endocrine resistance. Breast Cancer Res Treat 2005;93(Suppl 4):11-8. Abstract
Ferrari L et al. Could exemestane affect
insulin-like growth factors, interleukin 6
and bone metabolism in postmenopausal
advanced breast cancer patients after failure on
aminoglutethimide, anastrozole or letrozole? Int
J Oncol 2003;22(5):1081-9. Abstract
Forward DP et al. Clinical and endocrine data
for goserelin plus anastrozole as second-line
endocrine therapy for premenopausal advanced
breast cancer. Br J Cancer 2004;90(3):590-4.
Abstract
Franco S et al. Response to fulvestrant in
heavily pretreated postmenopausal women: A
single-center experience. Breast Cancer Res Treat 2004;88(2):103-8. Abstract
Gradishar W. Fulvestrant in the treatment of
postmenopausal women with advanced breast
cancer. Expert Rev Anticancer Ther 2005;5(3):445-
53. Abstract
Gralow JR. Optimizing the treatment of
metastatic breast cancer. Breast Cancer Res Treat 2005;89(Suppl 1):9-15. Abstract
Gutteridge E et al. Effects of fulvestrant on
estrogen receptor levels during long-term
treatment of patients with advanced breast
cancer — final results. Breast Cancer Res Treat 2004;Abstract 4086.
Howell A et al. Comparison of fulvestrant versus
tamoxifen for the treatment of advanced breast
cancer in postmenopausal women previously
untreated with endocrine therapy: A multinational,
double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract
Howell A et al. A review of the efficacy of
anastrozole in postmenopausal women with
advanced breast cancer with visceral metastases. Breast Cancer Res Treat 2003;82(3):215-22.
Abstract
Howell A et al. Fulvestrant, formerly ICI
182,780, is as effective as anastrozole in
postmenopausal women with advanced breast
cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403.
Abstract
Iaffaioli RV et al. Phase II study of sequential
hormonal therapy with anastrozole/exemestane
in advanced and metastatic breast cancer. Br J
Cancer 2005;92(9):1621-5. Abstract
Iaffaioli RV et al. Preliminary data of GOIM
2107 study: Multicenter phase II study of
sequential hormonotherapy with anastrozole/
exemestane in metastatic breast disease. Proc ASCO 2004;Abstract 820.
Ingle JN et al. Evaluation of fulvestrant in women
with advanced breast cancer and progression
on prior aromatase inhibitor therapy: A phase
II trial of the North Central Cancer Treatment
Group. Breast Cancer Res Treat 2004;Abstract 409.
Ingle JN. Sequencing of endocrine therapy in
postmenopausal women with advanced breast
cancer. Clin Cancer Res 2004;10(1 Pt 2):362-7.
Abstract
Ingle JN, Suman VJ. Aromatase inhibitors for
therapy of advanced breast cancer. J Steroid
Biochem Mol Biol 2005;95(1-5):113-9. Abstract
Irish W et al. Quality-adjusted survival in a
crossover trial of letrozole versus tamoxifen in
postmenopausal women with advanced breast
cancer. Ann Oncol 2005;16(9):1458-62. Abstract
Johnston S. Fulvestrant and the sequential
endocrine cascade for advanced breast cancer. Br
J Cancer 2004;90(Suppl 1):15-8. Abstract
Johnston SR et al. Life following aromatase
inhibitors - where now for endocrine sequencing? Breast Cancer Res Treat 2005;93 Suppl 4:19-25.
Abstract
Jones SE, Pippen J. Effectiveness and tolerability
of fulvestrant in postmenopausal women with
hormone receptor-positive breast cancer. Clin
Breast Cancer 2005;6(Suppl)1:9-14. Abstract
Jones SE et al. A retrospective analysis of the
proportion of patients responding for > 1
year in two phase III studies of fulvestrant vs
anastrozole. Proc ASCO 2004;Abstract 737.
Jones SE et al. A retrospective analysis of the
proportion of patients responding for ≥ 1,
1.5 and 2 years in two phase III studies of
fulvestrant vs anastrozole. Breast Cancer Res Treat 2004;Abstract 6047.
Kaufmann M et al. Exemestane improves survival
in metastatic breast cancer: Results of a phase
III randomized study. Clin Breast Cancer 2000;(1
Suppl 1):15-8. Abstract
Marcom PK et al. A phase II trial of letrozole
and trastuzumab for ER and/or PgR and HER2
positive metastatic breast cancer: Final results. Proc ASCO 2005;Abstract 596.
Mauriac L et al. Fulvestrant (Faslodex) versus
anastrozole for the second-line treatment
of advanced breast cancer in subgroups of
postmenopausal women with visceral and
nonvisceral metastases: Combined results
from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract
McKeage K et al. Fulvestrant: A review of its use
in hormone receptor-positive metastatic breast
cancer in postmenopausal women with disease
progression following antiestrogen therapy. Drugs 2004;64(6):633-48. Abstract
Milla-Santos A et al. Anastrozole versus
tamoxifen as first-line therapy in postmenopausal
patients with hormone-dependent
advanced breast cancer: A prospective,
randomized, phase III study. Am J Clin Oncol 2003;26(3):317-22. Abstract
Mouridsen H, Chaudri-Ross HA. Efficacy of
first-line letrozole versus tamoxifen as a function
of age in postmenopausal women with advanced
breast cancer. Oncologist 2004;9(5):497-506.
Abstract
Mouridsen H et al. Superiority of letrozole to
tamoxifen in the first-line treatment of advanced
breast cancer: Evidence from metastatic
subgroups and a test of functional ability. Oncologist 2004;9(5):489-96. Abstract
Mouridsen H et al. Phase III study of letrozole
versus tamoxifen as first-line therapy of
advanced breast cancer in postmenopausal
women: Analysis of survival and update of
efficacy from the International Letrozole Breast
Cancer Group. J Clin Oncol 2003;21(11):2101-9.
Abstract
Nabholtz JM et al. Anastrozole (Arimidex)
versus tamoxifen as first-line therapy for
advanced breast cancer in postmenopausal
women: Survival analysis and updated safety
results. Eur J Cancer 2003;39(12):1684-9.
Abstract
Osborne CK et al. Fulvestrant: An oestrogen
receptor antagonist with a novel mechanism
of action. Br J Cancer 2004;90(Suppl 1):2-6.
Abstract
Osborne CK et al. Double-blind, randomized
trial comparing the efficacy and tolerability
of fulvestrant versus anastrozole in
postmenopausal women with advanced breast
cancer progressing on prior endocrine therapy:
Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract
Paridaens R et al. First line hormonal treatment
(HT) for metastatic breast cancer (MBC) with
exemestane (E) or tamoxifen (T) in postmenopausal
patients (pts) — A randomized phase III
trial of the EORTC Breast Group. Proc ASCO 2004;Abstract 515.
Perey L et al. Fulvestrant (Faslodex) as hormonal
treatment in postmenopausal patients with
advanced breast cancer (ABC) progressing after
treatment with tamoxifen and aromatase inhibitors:
Update of a phase II SAKK trial. Breast Cancer Res Treat 2004;Abstract 6048.
Petruzelka L et al. Fulvestrant in postmenopausal
women with metastatic breast cancer
progressing on prior endocrine therapy —
Results from a compassionate use program. Proc ASCO 2004;Abstract 730.
Possinger K. Fulvestrant — A new treatment for
postmenopausal women with hormone-sensitive
advanced breast cancer. Expert Opin Pharmacother 2004;5(12):2549-58. Abstract
Pritchard KI. Endocrine therapy of advanced
disease: Analysis and implications of the
existing data. Clin Cancer Res 2003;9(1 Pt 2):460-
7. Abstract
Prowell TM, Davidson NE. What is the role of
ovarian ablation in the management of primary
and metastatic breast cancer today? Oncologist 2004;9(5):507-17. Abstract
Rivera E et al. Pilot study evaluating the pharmacokinetics,
pharmacodynamics, and safety of the
combination of exemestane and tamoxifen. Clin
Cancer Res 2004;10(6):1943-8. Abstract
Robertson JF et al. Endocrine treatment options
for advanced breast cancer — The role of
fulvestrant. Eur J Cancer 2005;41(3):346-56.
Abstract
Robertson JF et al. Sensitivity to further
endocrine therapy is retained following progression
on first-line fulvestrant. Breast Cancer Res Treat 2005;92(2):169-74. Abstract
Robertson JFR et al. Clinical efficacy of
fulvestrant and effects on estrogen receptor
levels during first-line endocrine treatment of
patients with advanced breast cancer. Breast Cancer Res Treat 2004;Abstract 6049.
Robertson JF et al. Fulvestrant versus anastrozole
for the treatment of advanced breast carcinoma
in postmenopausal women: A prospective
combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract
Sokolowicz LE, Gradishar WJ. Implications of
first-line adjuvant treatment with aromatase
inhibitors in recurrent metastatic breast
cancer. Clin Breast Cancer 2004(5 Suppl 1):24-30.
Abstract
Steger G et al. Fulvestrant (FUL) and goserelin
(GOS) in premenopausal women with advanced,
hormone-sensitive breast cancer — A pilot
study. Proc ASCO 2005;Abstract 708.
Steger GG et al. Fulvestrant (‘Faslodex’):
Clinical experience from the Compassionate Use
Programme. Cancer Treat Rev 2005;31 Suppl 2:
S10-6. Abstract
Thürlimann B et al. Anastrozole (‘Arimidex’)
versus tamoxifen as first-line therapy in
postmenopausal women with advanced
breast cancer: Results of the double-blind
cross-over SAKK trial 21/95 — a sub-study
of the TARGET (Tamoxifen or ‘Arimidex’
Randomized Group Efficacy and Tolerability)
trial. Breast Cancer Res Treat 2004;85(3):247-54.
Abstract
Thürlimann B et al; Arimidex Study Group.
Efficacy of tamoxifen following anastrozole
(‘Arimidex’) compared with anastrozole
following tamoxifen as first-line treatment
for advanced breast cancer in postmenopausal
women. Eur J Cancer 2003;39(16):2310-7.
Abstract
Traina TA et al. A feasibility study of an
aromatase inhibitor (AI), letrozole (L) and the
antibody to vascular endothelial growth factor
(VEGF), bevacizumab (B), in patients (pts) with
hormone receptor-positive metastatic breast
cancer (MBC). Proc ASCO 2005;Abstract 796.
Vergote I, Robertson JF. Fulvestrant is an effective
and well-tolerated endocrine therapy for
postmenopausal women with advanced breast
cancer: Results from clinical trials. Br J Cancer 2004;90(Suppl 1):11-4. Abstract
Vergote I et al; Trial 0020 Investigators.
Postmenopausal women who progress on
fulvestrant (‘Faslodex’) remain sensitive to
further endocrine therapy. Breast Cancer Res Treat 2003;79(2):207-11. Abstract
Vogel CL. Update on the current use of
hormonals as therapy in advanced breast cancer. Anticancer Drugs 2003;14(4):265-73. Abstract
|